Fig. 3: MLST8/mTORC2 loss improves effector function of cytotoxic T cells. | Cancer Gene Therapy

Fig. 3: MLST8/mTORC2 loss improves effector function of cytotoxic T cells.

From: Targeting mTORC2 in lung squamous cell carcinoma improves anti-tumor immunity through the PSGL-1-VISTA axis

Fig. 3

A Schematic diagram of experimental design showing H596 tumor allograft in Rag1null mice. B Flow cytometric analysis of CD8+ T cells in WT and MLST8-KO tumors. Flow cytometric analysis of CD25+ (C) and CD107a+ (D) in CD8+ T cells of WT and mLST8- KO tumors. E Schematic diagram of experimental design showing KLN205-Ptennull WT or Mlst8-KO tumor allograft in DBA/2 mice. Flow cytometric analysis of CD8+ in live cells (F) GZMB+ (G) and CD107a+ (H) in CD8+ T cells of WT and Mlst8-KO tumors. Each dot represents a mouse. All data are presented as mean ± SEM from two or three independent experiments. p values were determined by two-tailed unpaired Student t test. *p < 0.05, **p < 0.01, ns not statistically significant, FC Fold change.

Back to article page